Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 61413, Abha 9088, Saudi Arabia.
Department of Medicine, Xi'an Jiaotong University, China.
Dis Markers. 2022 Jan 29;2022:9997212. doi: 10.1155/2022/9997212. eCollection 2022.
Breast cancer is a heterogeneous disease and is the most common and prevalent form of malignancy diagnosed in women. lncRNAs are found to be frequently dysregulated in cancer, and its expression plays a critical role in tumorigenesis. The study included 100 histopathologically confirmed, newly diagnosed untreated patients of invasive ductal carcinoma (IDC) of breast cancer patients and 100 healthy subjects. After blood collection, the serum was separated and total RNA was extracted, cDNA was synthesized using 100 ng of total RNA, and lncRNA (ANRIL, TUG1, UCA1, and HIT) expression was analyzed. Increased ANRIL (3.83-fold), TUG1 (7.64-fold), UCA1 (7.82-fold), and HIT (3.31-fold) expressions were observed in breast cancer patients compared to healthy controls. Relative expression of lncRNAs UCA-1 ( = 0.010) and HIT-1 ( < 0.0001) was significantly elevated in patients with advanced breast cancer stage compared to those with early-stage disease. While lncRNA TUG-1 expression was found to be higher in patients with early-stage tumors than those with advanced-stage tumors ( = 0.06), lncRNA ANRIL showed increased expression in patients with PR positive status ( = 0.04). However, we found a significant difference in lncRNA HIT expression in HER-2 positive breast cancer patients compared to HER-2 negative breast cancer patients ( = 0.005). An increase in the expression of serum lncRNAs ANRIL ( < 0.0001), UCA-1 ( = 0.004), and HIT ( < 0.0001) was observed in the distant organ metastatic breast cancer patients. In the ROC curve concerning lymph node involvement, the sensitivity and specificity of lncRNA HIT were 68% and 58%, respectively ( value = 0.007). In the ROC curve w.r.t. stages of disease, the sensitivity and specificity of lncRNA HIT were 80% and 50%, respectively ( value < 0.0001). Better sensitivity and specificity were observed for lncRNA HIT (sensitivity 91% and specificity 78%; value < 0.0001) and ANRIL (sensitivity 70% and specificity 60%; value < 0.0001) w.r.t distant organ metastases.
乳腺癌是一种异质性疾病，也是女性中最常见和最普遍的恶性肿瘤形式。lncRNAs 被发现经常在癌症中失调，其表达在肿瘤发生中起着关键作用。该研究纳入了 100 例经组织病理学证实的新诊断为浸润性导管癌（IDC）的乳腺癌患者和 100 例健康对照者。采集血液后，分离血清并提取总 RNA，用 100ng 总 RNA 合成 cDNA，并分析 lncRNA（ANRIL、TUG1、UCA1 和 HIT）的表达。与健康对照组相比，乳腺癌患者的 ANRIL（3.83 倍）、TUG1（7.64 倍）、UCA1（7.82 倍）和 HIT（3.31 倍）表达增加。与早期疾病相比，晚期乳腺癌患者的 lncRNA UCA-1（ = 0.010）和 HIT-1（ < 0.0001）的相对表达显著升高。lncRNA TUG-1 的表达在早期肿瘤患者中高于晚期肿瘤患者（ = 0.06），而 lncRNA ANRIL 在 PR 阳性状态的患者中表达增加（ = 0.04）。然而，我们发现 HER-2 阳性乳腺癌患者与 HER-2 阴性乳腺癌患者之间的 lncRNA HIT 表达存在显著差异（ = 0.005）。远处器官转移的乳腺癌患者血清 lncRNAs ANRIL（ < 0.0001）、UCA-1（ = 0.004）和 HIT（ < 0.0001）的表达增加。在涉及淋巴结受累的 ROC 曲线中，lncRNA HIT 的灵敏度和特异性分别为 68%和 58%（ 值 = 0.007）。在疾病分期的 ROC 曲线中，lncRNA HIT 的灵敏度和特异性分别为 80%和 50%（ 值 < 0.0001）。lncRNA HIT（灵敏度 91%，特异性 78%； 值 < 0.0001）和 ANRIL（灵敏度 70%，特异性 60%； 值 < 0.0001）在远处器官转移方面表现出更好的灵敏度和特异性。
